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Analysis often reveals variability in the composition of ecstasy pills from pure 3,4-
methylenedioxymethamphetamine (MDMA) to mixtures of MDMA derivatives, amphetamine, and 
other unidentiﬁ ed substances. For a comprehensive toxicological analysis one needs to know all steps to 
MDMA synthesis which may originate impurities. The aim of this study was to synthesise and determine 
the chemical-physical and in vitro biological properties of a series of MDMA derivatives.
3,4-methylendioxyphenyl-2-nitropropene (MDNP) was obtained by condensation of piperonal 
with an excess of nitroethane in the presence of ammonium acetate. MDNP was then reduced to 
methylenedioxyamphetamine (MDA) by LiAlH
3
. All compounds were analysed using HPLC and 
spectroscopic technique [Raman, nuclear magnetic resonance (NMR), or infrared (IR)] at all the steps of 
synthesis. In addition, we assessed the biological potentials of these compounds by measuring in vitro their 
(i) blood cell/whole blood partition coefﬁ cient, (ii) binding to plasmatic proteins (Fbp), and (iii) membrane 
adsorption. Chemical structure was determined with antibody ﬂ uorescence polarisation immunoassay 
(FPIA). This study showed the presence of solid impurities, particularly of a neurotoxic compound of 
Al3+ in the ﬁ nal products. FPIA identiﬁ ed the aminoethane group close to the substituted benzene ring, 
but did not detect the two major precursors of MDMA: MDNP and piperonal. Raman spectroscopy is an 
attractive alternative technique to characterise ecstasy pills and it can identify stereoisomeric forms such 
as cis-MDNP and trans-MDNP, which exhibit signals at 1650 cm-1 and 1300 cm-1, respectively.
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Ecstasy is a synthetic drug used recreationally 
worldwide, especially by young people, which 
makes it a major public health concern (1). A recent 
French study with 1666 ecstasy pills carried out 
by a non-governmental organisation Rave Mission 
revealed that the pill composition varied from pure 
3,4-methylenedioxymethamphetamine (MDMA) 
to a mixture of ecstasy derivatives, amphetamine, 
and 20 % of other substances unidentiﬁ ed by Rapid 
Product Control (RCP) (2). There are several 
possible ways to synthesise ecstasy, all of them 
starting with piperonal to obtain either a ketone 
(3,4-methylenedioxyphylpropanone) or an amine 
chemical form (3,4-methylenedioxyamphetamine) (2). 
Various impurities and by-products were identiﬁ ed in 
powdered tablets: 3,4-methylenedioxyamphetamine 
(MDA), MDA or MDMA dimers, substituted 
pyridines, lead, aluminium, and nitroethane (3,4). 
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Some of these compounds are toxic and could be 
involved in documented cases of fulminant toxic 
hepatitis and neurotoxic effects (4).
This suggests that a comprehensive toxicological 
analysis of an ecstasy pill requires expert knowledge 
of all synthetic steps and identiﬁ cation of impurities. 
Raman spectroscopy is a powerful technique to 
characterise ecstasy pills. In addition, it is an in situ, 
non-destructive technique that identiﬁ es chemical 
bonds through intramolecular vibration spectrum 
(5-7). The technique has proven successful in several 
published studies of illegal drugs (8,9). In addition, 
Raman spectroscopy was used to probe photoexcitated 
phase transition with second irradiation using 
nanosecond pulsed laser leading for example to colour 
changes (10). These properties could be exploited to 
identify organic metals in a sample.
The aim of our study was to ﬁ rst synthesise a series 
of MDMA derivatives, then to characterise them using 
HPLC and spectroscopic techniques [Raman, nuclear 
magnetic resonance (NMR), or infrared (IR)], and 
ﬁ nally to establish their biological effects on blood 




Piperonal, lithium aluminium hydride (LiAlH
3
, 
1 mol L-1 in tetrahydrofuran), sodium borohydride 
(NaBH
4
















), and other solvents (all of pro analysis 
grade) were purchased from Acros Organics (Geel, 
Belgium). All reagents were used without further 
puriﬁ cation.
Synthesis
The synthesis started with piperonal (11), which 
was dissolved with excess of nitroethane in the 
presence of ammonium acetate, leading to 3,4-
methylendioxyphenyl-2-nitropropene (MDNP). 
MDA was obtained by reducing MDNP with LiAlH
3
. 
Typically, MDNP was prepared by reﬂ uxing a mixture 
of 25 mmol of piperonal (3.75 g), 133 mmol of 
nitroethane, 12.5 mmol of ammonium acetate, and 
60 mL of toluene. The mixture was heated overnight 
with continuous removal of water into a Dean-Starck 
tube. The solvent was then evaporated in vacuum 






Dropwise we carefully added 1.15 mmol of LiAlH
3
 
to 100 mL of the stirred solution of 0.05 mol L-1 
MDNP in tetrahydrofuran. The resulting mixture was 
heated for ﬁ ve hours. LiAlH
3
 was decomposed by 
H
2
O and the solid was removed by ﬁ ltration. MDA 
was dissolved in 20 mL of dichloromethane and 
washed with 500 mL of 1 mol L-1 sodium hydroxide 
solution.
To obtain 3,4-methylendioxyphenyl-2-nitropropane, 
we added NaBH
4
 (0.02 mol) to a solution of MDNP 
(0.01 mol) in methanol (25 mL) by stirring at 5 °C 
to 10 °C. After allowing the reaction to continue for 
another hour at room temperature, the mixture was 
concentrated. Excess of NaBH
4
 was decomposed with 
acetic acid and extracted with chloroform.
CHARACTERISATION
HPLC
The precursor and ﬁ nal products were determined 
by HPLC equipped with a UV detector. The mobile 
phase consisted of methanol:H
2
O:triﬂ uoroacetic acid 
(60:40:0.01). Eluation was in isocrat mode at the ﬂ ow 
rate of 1 mL min-1. HPLC separation was performed 
on a reverse-phase C
18
 column (LiChrospher 60, 
RP-select B ,125 mm x 4 mm, with 5 µm sized 
particles).
NMR spectroscopy
1H and 13C NMR spectra were acquired at 
250.13 MHz on a Bruker WM250 spectrometer. 
Chemical shifts are given in ppm vs. tetramethylsilane 




SO as solvent 
(d1H=2.62 ppm and d13C=39.6 ppm).
Raman spectroscopy
Spectra were acquired using a Dilor XY1800 
triplemate spectrograph coupled to a Princeton 
Instruments CCD detector. The 647.1 nm line of a 
Kr+ laser (Coherent Radiation Innova) was used as the 
excitation source with laser power of 50 mW. Raman 
signals were collected at room temperature, at 180 °C 
to the incident laser beam in the 170 cm-1 to 2400 cm-1 
frequency range. Rayleigh scattering was removed 
using a holographic notch ﬁ lter.
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Infrared spectroscopy
IR spectra were recorded on KBr discs with a 
Perkin-Elmer 983 spectrometer. For all the studied 
compounds we scanned four accumulations between 
400 cm-1 and 4000 cm-1 with 2 cm-1 resolution.
Biological characterisation
The biological potentials of compounds were 
assessed from in vitro measurements of their 
fraction bound to plasma proteins coefﬁ cient (F
bp
), 
determination of blood cell/whole blood partition 
coefﬁ cient (F
cb
), membrane adsorption coefﬁ cient 
(F
ad
), and interaction with specific anti-MDMA 




200 µL of plasma spiked with the studied 
compound (0.1 nmol L-1) was incubated in a water bath 
at 37 °C for 15 min and placed in an ultraﬁ ltration cell. 
After centrifugation in an SM24 centrifuge (Dupont 
Instruments; Wilmington, DE, USA) at 1978 g for 
20 min, the ultraﬁ ltrate was analysed using HPLC. The 
unbound to protein fraction (F
up
) was determined by 
calculating the ratio of the concentration in ultraﬁ ltrate 
and the initial compound concentration in plasma. The 
fraction bound to plasma proteins was deducted from 







20 µL of physiological solution of each compound 
at concentration of 1 mmol L-1 was added to 2 mL 
fresh blood taken on EDTA tripotassium salt 
(K
3
EDTA). After incubation for 15 min at 37 °C, 
the blood sample was centrifuged (at 2000 g for 
15 min) and 200 µL plasma were taken to determine 
the concentration in the ultraﬁ ltrate (see determining 
F
bp













The free fraction, which is neither bound to 











 is the blood cell/whole blood partition 
coefficient; C
bt
 the concentration in total blood 
(0.01 mmol L-1); C
uf
 the concentration in ultraﬁ ltrate; 
F
up
 the unbound-to-protein fraction coefﬁ cient; h is 
haematocrit; F
bp
 binding to plasma proteins coefﬁ cient, 
and F
fr
 the free fraction coefﬁ cient.
Determination of F
ad
200 µL of physiological solution of each compound 
(1 µmol L-1) were centrifuged through permeable 
anisotropic membrane (Amicon) at 1978 g for 20 min 
(SM24 centrifuge, Dupont Instruments; Wilmington, 
DE, USA) and the ultraﬁ ltrate was analysed using 
HPLC. The coefﬁ cient of membrane adsorption was 











 is the membrane adsorption coefﬁ cient; 
C
is
 the concentration in initial physiological solution; 
and C
su
 the concentration in the ultraﬁ ltrate.
Interaction with speciﬁ c anti-MDMA antibody
Physiological solution of each compound 
(0.01 mmol L-1) was analysed using an automated 
FPIA system (Abbott AxSYM®, USA).
RESULTS AND DISCUSSION
In this study, we have described the synthesis 
route starting from piperonal and ending with 3,4-
methylenedioxyamphetamine (MDA) (11). We have 
also reported the synthesis of  3,4 methylendioxyphenyl-
2-nitropropane, which is not considered precursor 
of MDMA. We used 3,4 methylendioxyphenyl-2-
nitropropane to study its interaction with speciﬁ c 
anti-MDMA antibody.
MDNP and MDA were obtained with high 
chemical purity. The synthesis reactions were 
followed by HPLC determination of retention times 
of the obtained products. Piperonal, MDA and MDNP 
exhibited high lipophilicity (Figure 1). The retention 
Figure 1  HPLC patterns of piperonal and synthesised MDNP 
and MDA
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times of piperonal, MDA, and MDNP were 2 min, 
2.5 min, and 3.1 min, respectively, and correlated to 
their lipophilicity (13).
IR and NMR spectroscopies showed a clear proﬁ le 
of piperonal, MDNP, and MDA. NMR detected the 
following signals:
1H NMR: d=1.22 (d, J=6.2 Hz, 3 H, CH
3
), 2.71 
(dd, J=13.4 and 8.8 Hz, 1H, CH
2
), 3.07 (dd, J=13.4 
and 5.2 Hz, 1H, CH
2
), 3.43 (m, 1H, CH), 6.10 (s, 2 H, 
CH
2
), 6.80 (dd, J=7.8 and 1.3 Hz, 1H, C
4
H), 6.97 (d, 
J=1.3 Hz, 1H, C
6
H), 6.97 (d, J=7.8 Hz, 1H, C
3
H).




), 48.2 (CH), 
101.0 (CH
2














IR (Figure 2) revealed signals related to benzene 
ring (absorption at 1603 cm-1, 1505 cm-1, 1680 cm-1, 
and 1489 cm-1), to ether oxide bridge at 1489 cm-1, 
and to MDMA derivatives.
For piperonal, the band located at 1677 cm-1 
revealed the presence of aldehyde, for MDNP the 
band at 1510 cm-1 indicated a nitro compound in 
position alpha of an unsaturated bond, and MDA was 
characterised by bands at 3358 cm-1 and 1634 cm-1 
pointing to amines, and by the disappearance of the 
nitro signals.
Figure 2 shows the vibrational modes of piperonal, 
MDNP, and MDA plotted in the range of 250 cm-1 to 
1750 cm-1. While piperonal and MDNP showed high 
quality Raman spectra (Figure 3), MDA showed a 
spectrum with a rather large background, possibly 
due to a ﬂ uorescence in the system at either 632 nm or 
541 nm (Figure 4). Milhazes et al. (9) obtained MDA 
spectrum at 541 nm.
Table 1 lists the biological characteristics of the 
ecstasy derivatives and impurities in the ﬁ nal product. 
Of solid impurities found, a neurotoxic compound 
of Al3+ is of particular interest (4). Save for F
bp
, all 
other biological parameters seem to be proportional 
to their retention time determined by HPLC and to 
their lipophilicity. Retention times for piperonal was 
2 min, for MDA and 2.5 min, and for MDNP 3.1 min 





Table 1 shows that the percent of free compounds in 
plasma is less than 40 % of total blood concentration: 
F
fr
=23 % for piperonal, F
fr
=27 % for MDA, and 
F
fr
=38 % for MDNP.
FPIA antibody recognised the aminoethane group 
close to the substituted benzene ring, but did not detect 
the two major precursors of MDMA, that is, MDNP 
and piperonal (Figure 5). This limitation must be 
taken into consideration, as detection of all ecstasy 
Figure 2  Infrared spectra of (a) piperonal, (b) MDNP, and 
(c) MDA
derivatives is required to optimise performance of 
detection methods.
CONCLUSION
This study has detected solid impurities and 
by-products in the synthesised products: MDA, 
unreacted piperonal, MDNP, and aluminium. While 
HPLC, Raman, and IR spectroscopy identiﬁ ed ecstasy 
derivatives, FPIA did not detect MDNP and piperonal. 
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Table 1 Biological characteristics of ecstasy derivatives and impurities in the ﬁ nal product
F
bp




 / % Fad / % Derivatives and impurities FPIA
Piperonal 63 38 23 47  Negative





MDA 71 30 27 63 MDNP (s) , THF (l), Al3+ (s) Positive
(l) liquid; (s) solid
MDNP: 3,4-methylendioxyphenyl-2-nitropropene; MDA: 3,4-methylenedioxyamphetamine; FPIA: ﬂ uorescence polarization 
immunoassay; F
bp
: blood cell/whole blood partition coefﬁ cient; F
fr
: free fraction coefﬁ cient; F
cb
: binding to plasmatic proteins 
coefﬁ cient; F
ad
: membrane adsorption coefﬁ cient; THF: tetrahydrofuran; NH
4
Ac: ammonium acetate; EtNO
2
: nitroethane
Figure 3 Raman spectra of piperonal and MDNP
Figure 4 Raman spectrum of MDA
Figure 5  Molecules tested in vitro with ﬂ uorescence polarization 
immunoassay (FPIA). (1) piperonal; (2) MDNP; (3) 
3,4-methylendioxyphenyl-2-nitropropane; and (4) 
MDA.
Raman spectroscopy has turned out to be a particularly 
interesting alternative technique for characterising 
ecstasy pills, as it can determine stereoisomeric forms 
of compound such as cis-MDNP and trans-MDNP at 
1650 cm-1 and 1300 cm-1, respectively.
Our findings call for further study of Raman 
spectroscopy to better characterise other drug 
derivatives.
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Sažetak
TOKSIKOLOŠKE METODE OTKRIVANJA OPOJNIH DROGA U TRAGOVIMA:
KROMATOGRAFSKA, SPEKTROSKOPSKA I BIOLOŠKA KARAKTERIZACIJA DERIVATA 
ECSTASYJA
Analize često otkriju neujednačenost sastava tableta ecstasyja od čistoga 3,4-metilendioksimetamfetamina 
(MDMA) do mješavina njegovih derivata, amfetamina i drugih neutvrđenih tvari. Stoga je za kvalitetnu 
toksikološku analizu potreban uvid u sve korake sinteze MDMA, s obzirom na to da se ondje vjerojatno 
kriju izvori nečistoće (prekursori, katalizatori). Cilj ovog ispitivanja bio je sintetizirati derivate MDMA 
te napraviti njihovu kemijsko-ﬁ zikalnu i biološku in vitro karakterizaciju.
3,4-metilendioksifenil-2-nitropropen (MDNP) dobiven je kondenzacijom piperonala u suvišku nitroetana uz 
dodatak amonijeva acetata. Njegovom redukcijom s pomoću LiAlH
3
 dobiven je 3,4-metilendioksiamfetamin 
(MDA). Svi spojevi iz pojedinih koraka sinteze karakterizirani su s pomoću tekućinske kromatograﬁ je 
visoke djelotvornosti (HPLC) i spektroskopskih tehnika [Ramanove spektroskopije, nuklearne magnetske 
rezonancije (NMR-a) te infracrvene spektroskopije (IR-a)]. Usto je ocijenjen i njihov biološki učinak 
in vitro mjerenjem (i) koeﬁ cijenta raspodjele krvna stanica/puna krv, (ii) vezanja za bjelančevine u 
plazmi (Fbp) te (iii) adsorpcije na membranu. Kemijska je struktura utvrđena s pomoću ﬂ uorescentnoga 
polarizacijskog imunokemijskog testa (FPIA). Analiza je u konačnim proizvodima utvrdila prisutnost krutih 
nečistoća, napose spojeva neurotoksičnog aluminija (Al3+). FPIA je prepoznao aminoetansku skupinu blizu 
supstituiranoga benzenskog prstena, ali ne i dva glavna prekursora za MDMA: MDNP i piperonal. Posebno 
je zanimljiva Ramanova spektroskopija budući da (i) pruža privlačnu alternativu za karakterizaciju sastava 
tableta ecstasyja te (ii) može otkriti stereoizomerne cis/trans-oblike spoja poput cis-MDNP-a odnosno 
trans-MDNP-a, čiji se signal vidi na 1650 cm-1 odnosno 1300 cm-1.
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